A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-509372-41-00
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS